Shots:

• The companies expanded their license agreement for the research and development of an additional gene therapy for a lysosomal storage disorder. Takeda has exercised its option to initiate a fourth program based on the results from three initial programs
• Following the Mar’2020 agreement- Codexis has created the novel enzyme sequences to advance gene therapies into pre-clinical development by utilizing its CodeEvolver protein engineering platform
• Takeda is responsible for the pre/ clinical development and commercialization of gene therapy products emerges from the collaboration

  Ref: GlobeNewswire | Image: Takeda